CA 125 and vascular endothelial growth factor in the differential diagnosis of epithelial ovarian tumors

Gynecologic and Obstetric Investigation

Volumn 54, Issue 3, 2002, Pages 132-136

  Candido Dos Reis, Francisco José ^a   De Andrade, Jurandyr Moreira ^a   Bighetti, Sérgio ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Angiogenesis; CA 125; Ovarian carcinoma; Ovarian epithelial tumors; Vascular endothelial growth factor

Indexed keywords

CA 125 ANTIGEN; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD VESSEL PERMEABILITY; CHEMOLUMINESCENCE; CIRCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYST FLUID; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; OVARY TUMOR; PRIORITY JOURNAL; SERUM;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; CARCINOMA; CHEMILUMINESCENT MEASUREMENTS; CYST FLUID; ENDOTHELIAL GROWTH FACTORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MIDDLE AGED; OVARIAN CYSTS; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036980674     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000067877     Document Type: Article

References (24)

1. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-887.
2. Halila H, Huhtala ML, Huglund C, Nordling S, Stenman VH: Tumor-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEA. Br J Cancer 1987;56:153-156.
3. Folkman J: The role of angiogenesis in tumor growth. Semin Cancer Biol 1992;3:65-71.
4. Paweletz N, Knierim M: Tumor-related angiogenesis. Crit Rev Oncol Hematol 1989;9:197-242.
5. Senger DR, Galli SJ, Dvorak AM, Perruzi CA, Harvey VS, Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascitis fluid. Science 1983;219:983-985.
6. Hazelton D, Nicosia RF, Nicosia SV: Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. Clin Cancer Res 1999;5:823-829.
7. Babson AL: The IMMULITE automated immunoassay system. J Clin Immunoassay 1991; 14:83-88.
8. Crombach G, Zippel HH, Wurz H: Clinical significance of cancer antigen 125 (CA 125) in ovarian cancer. Cancer Detect Prev 1985;8:135-139.
9. Heinonen PK, Tontti K, Koivula T, Pystynen P: Tumor-associated antigen CA 125 in patients with ovarian cancer. Br J Obstet Gynaecol 1985;92:528-531.
10. Takahashi K, Shibukawa T, Moriyama M, Shirai T, Kijima S, Iwanari O, et al: Clinical usefulness and false-positive results of CA 125 as a tumor marker of ovarian cancer - a study on 674 patients. Jpn J Surg 1986;16:305-310.
11. Mogensen O, Mogensen B, Jakobsen A, Sell A: Preoperative measurement of cancer antigen 125 (CA 125) in the differential diagnosis of ovarian tumors. Acta Oncol 1989;28:471-473.
12. Rice LW, Lage JM, Berkowitz RS, Goodman A, Muto MG, Knapp RC, et al: Preoperative serum CA-125 levels in borderline tumors of the ovary. Gynecol Oncol 1992;46:226-229.
13. Patsner B: Preoperative serum CA-125 levels in early stage ovarian cancer. Eur J Gynaecol Oncol 1990;11:319-321.
14. Mann WJ, Patsner B, Cohen H, Loesch M: Preoperative serum CA-125 levels in patients with surgical stage I invasive ovarian adenocarcinoma. J Natl Cancer Inst 1988;80:208-209.
15. Fleuren JG, Nap M, Aalders JG, Trimbos JB, de Bruijn HWA: Explanation of the limited correlation between tumor CA 125 and serum CA 125 antigen levels in patients with ovarian tumors. Cancer 1987;60:2437-2442.
16. Senger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, et al: Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 1993;12:303-324.
17. Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, et al: Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989;84:1470-1478.
18. Nagy JA, Masse EM, Herzberg KT, Meyers MS, Yeo KT, Yeo TK, et al: Pathogenesis of ascitis tumor growth: Vascular permeability factor, vascular hyperpermeability, and ascitis fluid accumulation. Cancer Res 1995;55:360-368.
19. Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P, et al: Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999;85:178-187.
20. Paley PJ, Staskus KA, Gebhard K, Mohanraj D, Twiggs LB, Carson LF, et al: Vascular endothelial growth factor expression in early-stage ovarian carcinoma. Cancer 1997;80:98-106.
21. Yamamoto S, Konishi I, Mandai M, Kuroda H, Komatsu T, Nanbu K, et al: Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: Correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 1997;76:1221-1227.
22. Nagele F, Petru E, Medl M, Kainz C, Graf AH, Sevelda P: Preoperative CA 125: An independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1995;86:259-264.
23. Boss EA, Massuger LF, Thomas CM, Geurts-Moespot A, Boonstra H, Sweep CG: Vascular endothelial growth factor in ovarian cyst fluid. Cancer 2001;91:371-377.
24. Davis HM, Zurawski VR Jr, Bast RC Jr, Klug TL: Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. Cancer Res 1986;46:6143-6148.